doheny logo.png
Doheny Eye Institute To Receive Funding from NIH Award Supporting Cerebral Small Vessel Disease Detection
October 02, 2024 13:47 ET | Doheny Eye Institute
Yuhua Zhang, Ph.D., Principal Investigator at Doheny Eye Institute and Professor of Ophthalmology at the David Geffen School of Medicine, UCLA, will lead the development of the next generation of...
ocugen_4C_LOGO (002).png
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
October 02, 2024 06:30 ET | Ocugen
MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024 07:30 ET | Ocugen
MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ONL logo.jpg
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
September 13, 2024 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ocugen_4C_LOGO (002).png
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
September 09, 2024 06:30 ET | Ocugen
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
September 05, 2024 10:52 ET | Boehringer Ingelheim
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...
ocugen_4C_LOGO (002).png
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
September 05, 2024 07:00 ET | Ocugen
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 07:30 ET | Ocugen
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
August 28, 2024 06:30 ET | Ocugen
MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
August 26, 2024 07:02 ET | Ocugen
MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...